Pipeline PredictorRx™ evaluates new drugs, expected to have a significant clinical or financial impact when approved by the FDA, and compares them to current therapies.
This UMass Medical School model, entirely independent of drug company interests, goes beyond detailing pharmacy outcomes for pipeline drugs — we also examine the potential for avoiding hospitalization and other medical costs.